This BET-PROTAC compounds have shown high activity in some hematological malignancies, like mantle lymphoma or acute myeloid leukemia (AML), compared with BETi [16], but no particularly result has been reported in breast cancer. This evidence concerns the gene DNER and acute myeloid leukemia.